| | [Table 1.2] |
|---|
| | 2007 | 2008 | 2009 | 2010 | 2011 |
| | € million | € million | € million | € million | € million |
| Bayer Group | | | | | |
| Sales | 32,385 | 32,918 | 31,168 | 35,088 | 36,528 |
| Sales outside Germany | 85.1% | 85.4% | 86.7% | 87.4% | 87.3% |
| EBIT (operating result) | 3,154 | 3,544 | 3,006 | 2,730 | 4,149 |
| EBIT before special items1 | 4,287 | 4,342 | 3,772 | 4,452 | 5,025 |
| EBITDA1 | 5,866 | 6,266 | 5,815 | 6,286 | 6,918 |
| EBITDA before special items1 | 6,777 | 6,931 | 6,472 | 7,101 | 7,613 |
| Income before income taxes | 2,234 | 2,356 | 1,870 | 1,721 | 3,363 |
| Income after taxes | 4,716 | 1,724 | 1,359 | 1,310 | 2,472 |
| Earnings per share (€)2 | 5.84 | 2.22 | 1.70 | 1.57 | 2.99 |
| Noncurrent assets | 34,712 | 35,351 | 34,049 | 33,188 | 32,697 |
| of which goodwill and other intangible assets | 22,770 | 22,598 | 21,546 | 20,163 | 19,455 |
| of which property, plant and equipment | 8,819 | 9,492 | 9,409 | 9,835 | 9,823 |
| Current assets | 16,582 | 17,152 | 16,993 | 18,318 | 20,068 |
| Inventories | 6,217 | 6,681 | 6,091 | 6,104 | 6,368 |
| Receivables and other current assets | 7,834 | 8,377 | 8,177 | 9,374 | 11,846 |
| Cash and cash equivalents | 2,531 | 2,094 | 2,725 | 2,840 | 1,770 |
| Financial liablities | 14,417 | 16,870 | 12,949 | 11,833 | 11,679 |
| Noncurrent | 13,081 | 10,614 | 11,460 | 9,944 | 7,995 |
| Current | 1,336 | 6,256 | 1,489 | 1,889 | 3,684 |
| Interest expense – net | (701) | (702) | (548) | (499) | (335) |
| Return on equity | 31.8% | 10.4% | 7.7% | 6.9% | 13.0% |
| Gross cash flow3 | 4,784 | 5,295 | 4,658 | 4,771 | 5,172 |
| Capital expenditures (total) | 1,905 | 1,982 | 1,669 | 1,621 | 1,666 |
| Depreciation and amortization | 2,478 | 2,570 | 2,660 | 2,571 | 2,521 |
Personnel expenses
(including pension expenses) |
7,571 |
7,491 |
7,776 |
8,099 |
8,726 |
| Number of employees4 (Dec. 31) | 106,200 | 108,600 | 111,000 | 111,400 | 111,800 |
| Research and development expenses | 2,578 | 2,653 | 2,746 | 3,053 | 2,932 |
Equity including non-controlling interest
(total) |
16,821 |
16,340 |
18,951 |
18,896 |
19,271 |
| Capital stock | 1,957 | 1,957 | 2,117 | 2,117 | 2,117 |
| Reserves | 14,864 | 14,383 | 16,834 | 16,779 | 17,154 |
| Net income | 4,711 | 1,719 | 1,359 | 1,301 | 2,470 |
| Non-controlling interest | 87 | 77 | 54 | 63 | 59 |
| Liabilities (total) | 34,557 | 36,171 | 32,091 | 32,610 | 33,494 |
| Total assets | 51,378 | 52,511 | 51,042 | 51,506 | 52,765 |
| Equity ratio | 32.7% | 31.1% | 37.1% | 36.7% | 36.5% |
| |
|
|
|
|
|
| Bayer AG | | | | | |
| Net income | 1,928 | 1,161 | 2,226 | 1,245 | 1,134 |
Allocation to (withdrawal from) retained
earnings |
896 |
91 |
1,068 |
5 |
(239) |
| Total dividend payment | 1,032 | 1,070 | 1,158 | 1,240 | 1,364 |
| Dividend per share (€) | 1.35 | 1.40 | 1.40 | 1.50 | 1.65 |
1 For definition see Combined Management Report, Chapter 4.2 “Calculation of EBIT(DA) Before Special Items.” 2 Earnings per share: as defined in IAS 33: net income divided by the average number of shares. For details see Note [16] to the consolidated financial statements. 3 For definition see Chapter 4.5 “Liquidity and Capital Expenditures of the Bayer Group.” 4 Full-time equivalents |